Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Psoriasis biologics: a new era of choice.

Mahil SK, Smith CH.

Lancet. 2019 Sep 7;394(10201):807-808. doi: 10.1016/S0140-6736(19)31772-6. Epub 2019 Aug 8. No abstract available.


Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).

Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, Smith CH; BADBIR study group and the PSORT consortium.

Br J Dermatol. 2019 Jul 8. doi: 10.1111/bjd.18333. [Epub ahead of print]


Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic.

Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH.

Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17741. [Epub ahead of print]


An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target.

Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, Smith CH, Trembath RC, Peakman M, Wright J, Ciccarelli FD, Barker JN, Capon F.

Sci Transl Med. 2017 Oct 11;9(411). pii: eaan2514. doi: 10.1126/scitranslmed.aan2514. Erratum in: Sci Transl Med. 2017 Dec 13;9(420):.


Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.


AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production.

Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, Irvine AD, Képíró L, Mockenhaupt M, Oon HH, Pinner J, Ranki A, Seyger MMB, Soler-Palacin P, Storan ER, Tan ES, Valeyrie-Allanore L, Young HS, Trembath RC, Choon SE, Szell M, Bata-Csorgo Z, Smith CH, Di Meglio P, Barker JN, Capon F.

J Invest Dermatol. 2016 Nov;136(11):2251-2259. doi: 10.1016/j.jid.2016.06.618. Epub 2016 Jul 5.


Update on psoriasis immunopathogenesis and targeted immunotherapy.

Mahil SK, Capon F, Barker JN.

Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16. Review.


PSORIASIS: FROM GENE TO CLINIC CONGRESS REPORTInternational conference showcases cutting-edge psoriasis research.

Mahil SK.

J Clin Aesthet Dermatol. 2015 Jul;8(7 Suppl 3):17-22. Review. No abstract available.


Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris.

Berki DM, Liu L, Choon SE, David Burden A, Griffiths CEM, Navarini AA, Tan ES, Irvine AD, Ranki A, Ogo T, Petrof G, Mahil SK, Duckworth M, Allen MH, Vito P, Trembath RC, McGrath J, Smith CH, Capon F, Barker JN.

J Invest Dermatol. 2015 Dec;135(12):2964-2970. doi: 10.1038/jid.2015.288. Epub 2015 Jul 23.


A case of tuberculous lymphadenitis associated with subepidermal immunobullous disease.

Alwan W, Mahil SK, Banerjee P, Daramola O, Giles A, Hoque S, Groves R.

Clin Exp Dermatol. 2015 Dec;40(8):946-8. doi: 10.1111/ced.12624. Epub 2015 Mar 21. No abstract available.


Genetics of psoriasis.

Mahil SK, Capon F, Barker JN.

Dermatol Clin. 2015 Jan;33(1):1-11. doi: 10.1016/j.det.2014.09.001. Review.


Measles in a previously vaccinated human immunodeficiency virus-positive adult.

Mahil SK, Fleming J, Robson A, Sarkany R.

Clin Exp Dermatol. 2014 Jan;39(1):117-8. doi: 10.1111/ced.12238. Epub 2013 Nov 7. No abstract available.


New blisters in a patient treated for Stevens-Johnson syndrome/toxic epidermal necrolysis.

Mahil SK, Martin B, Creamer D, Smith CH.

Clin Exp Dermatol. 2014 Jan;39(1):63-5. doi: 10.1111/ced.12194. Epub 2013 Oct 3. No abstract available.


Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study': reply from authors.

Mahil SK, Smith CH.

Br J Dermatol. 2013 Nov;169(5):1170-1. doi: 10.1111/bjd.12511. No abstract available.


Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris.

Berki DM, Mahil SK, David Burden A, Trembath RC, Smith CH, Capon F, Barker JN.

J Invest Dermatol. 2014 Jan;134(1):271-273. doi: 10.1038/jid.2013.285. Epub 2013 Jun 21. No abstract available.


Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH.

Br J Dermatol. 2013 Aug;169(2):306-13. doi: 10.1111/bjd.12341.


Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature.

Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH.

J Dermatolog Treat. 2013 Feb;24(1):38-49. doi: 10.3109/09546634.2012.660520. Epub 2012 Mar 11. Review.


Supplemental Content

Loading ...
Support Center